Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Aldeyra Therapeutics, Inc.”

38 pharma patents match "Aldeyra Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 38
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 38 pharmaceutical patents matching "Aldeyra Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

38 results for “Aldeyra Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12240816

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  2. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  3. US 12097188

    Compositions and methods for the treatment of macular degeneration

    Aldeyra Therapeutics, Inc. · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  4. US 12064516

    Pharmaceutical formulations and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  5. US 12029735

    Polymorphic compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  6. US 12005061

    Ophthalmic formulations of methotrexate

    Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  7. US 12005060

    Ophthalmic formulations of methotrexate

    Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  8. US 12006298

    Polymorphic compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  9. US 11911385

    Methotrexate treatment methods

    Aldeyra Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  10. US 11845722

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  11. US 11786518

    Ophthalmic formulations and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  12. US 11771664

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  13. US 11724987

    Compositions and methods of treating retinal disease

    Aldeyra Therapeutics, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  14. US 11701331

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  15. US 11583529

    Treatment of inflammatory disorders

    Aldeyra Therapeutics, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  16. US 11459300

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  17. US 11312692

    Polymorphic compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  18. US 11197821

    Formulations for treatment of dry eye disease

    Aldeyra Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted
  19. US 11129823

    Combination treatment of ocular inflammatory disorders and diseases

    Aldeyra Therapeutics, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted
  20. US 11046650

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Jun 29, 2021 · Expires Jun 24, 2041

    granted
  21. US 11040039

    Treatment of inflammatory disorders

    Aldeyra Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  22. US 11007157

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  23. US 10913722

    Compositions and methods of treating retinal disease

    Aldeyra Therapeutics, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  24. US 10588874

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted